Baird Financial Group’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-61,586
| Closed | -$706K | – | 1812 |
|
|
2023
Q3 | $706K | Buy |
61,586
+940
| +2% | +$10.8K | ﹤0.01% | 1210 |
|
|
2023
Q2 | $1.53M | Sell |
60,646
-927
| -2% | -$23.5K | ﹤0.01% | 989 |
|
|
2023
Q1 | $1.98M | Buy |
61,573
+2,013
| +3% | +$64.8K | ﹤0.01% | 888 |
|
|
2022
Q4 | $1.1M | Buy |
59,560
+516
| +0.9% | +$9.53K | ﹤0.01% | 1043 |
|
|
2022
Q3 | $1.59M | Buy |
+59,044
| New | +$1.59M | ﹤0.01% | 912 |
|
|
2021
Q4 | – | Sell |
-48,515
| Closed | -$1.35M | – | 1943 |
|
|
2021
Q3 | $1.35M | Buy |
48,515
+9,488
| +24% | +$264K | ﹤0.01% | 1083 |
|
|
2021
Q2 | $1.16M | Buy |
39,027
+11,760
| +43% | +$349K | ﹤0.01% | 1135 |
|
|
2021
Q1 | $762K | Buy |
+27,267
| New | +$762K | ﹤0.01% | 1235 |
|
|
2020
Q4 | – | Sell |
-19,244
| Closed | -$484K | – | 1605 |
|
|
2020
Q3 | $484K | Buy |
19,244
+3,503
| +22% | +$88.1K | ﹤0.01% | 1163 |
|
|
2020
Q2 | $384K | Buy |
+15,741
| New | +$384K | ﹤0.01% | 1216 |
|
|
2016
Q3 | – | Sell |
-94,308
| Closed | -$1.28M | – | 1231 |
|
|
2016
Q2 | $1.28M | Sell |
94,308
-11,957
| -11% | -$163K | 0.01% | 668 |
|
|
2016
Q1 | $1.86M | Buy |
106,265
+23,655
| +29% | +$413K | 0.02% | 552 |
|
|
2015
Q4 | $2.82M | Buy |
82,610
+13,114
| +19% | +$448K | 0.03% | 460 |
|
|
2015
Q3 | $2.07M | Buy |
69,496
+35,315
| +103% | +$1.05M | 0.02% | 504 |
|
|
2015
Q2 | $1.09M | Buy |
+34,181
| New | +$1.09M | 0.01% | 730 |
|